Printer Friendly

COMPANY INFORMATION
Resverlogix Corp. 202-279 Midpark Way SE Calgary, AB T2X 1M2 Tel: (403) 254-9252 Fax: (403) 256-8495 Contact Name Donald J. McCaffrey Industry Pharmaceuticals		Key Executives Donald J. McCaffrey, CEO A. Brad Cann, CFO Researches and develops technology regulating the levels of high-density lipoprotein (HDL) cholesterol.
FP ADVISOR COVERAGE Resverlogix Corp. • FP Corporate Analyzer • FP Directory of Directors • FP Corporate Surveys • FP Predecessor & Defunct • Ordering FP Products		TOP INDUSTRY PLAYERS Pharmaceuticals Company Name Revenue ($000s)  Biovail Corporation 807,909 Patheon Inc. 765,812 Cangene Corporation 238,751 Dragon Pharmaceutical, Inc. 162,127 Paladin Labs Inc. 82,744 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF FEB 8/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX/RVX $2.92 $4.30 $2.10 n.a. n.a. n.a. 1.77 Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap. (000s) 107,118 n.a. $-0.60 Oct. 31/09 3.55% -48.11% -11.24% $115,101
ANNUAL FINANCIALS Periods ended: 12m Apr. 30/09 12m Apr. 30/08 12m Apr. 30/07 $000s $000s $000s Net income (21,611) (28,378) (18,330) Total assets 22,570 20,895 16,612 $ $ $ Earnings per share* (0.73) (1.10) (0.76) % % % Return on equity (223.39) n.m. n.m.   * Common
TRAILING 12-MONTH VALUES Periods ended: Oct. 31/09 Oct. 31/08 $000s $000s Net income (21,019) (24,193) $ $ Earnings per share (0.64) (0.90)

COMPANY NEWS

Results for 'Resverlogix Corp.' from past 30 days: No hits. (Links are to articles.)